What are the side effects of B7-33?
The most commonly reported B7-33 side effects are limited human data, theoretical hypotensive effect, injection-site reaction. Most are mild and tend to be dose dependent. It is generally avoided with hypotension or unstable cardiovascular status. Human clinical evidence for B7-33 is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported B7-33 side effects
- Limited human data
- Theoretical hypotensive effect
- Injection-site reaction
Who should avoid it
- Hypotension or unstable cardiovascular status
- Pregnancy / nursing
- Anyone risk-averse to pre-clinical-only data
References
- B7-33, single-chain peptide derivative of relaxin retains anti-fibrotic activity without hemodynamic effects — Hossain MA et al., Chem Sci, 2016
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) — Marshall SA, O'Sullivan K, Ng HH, et al., European Journal of Pharmacology, 2017
- Single chain peptide agonists of relaxin receptors — Praveen P, Kocan M, Valkovic A, et al., Molecular and Cellular Endocrinology, 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on B7-33
Last updated 2026-06-06.